Form 4 for BIIB Biogen
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0000875045-26-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-10 | 2026-02-06 | BIIB | Grogan Jane | Head of Research | F - Tax | $201.18 | -991 | 2,769 | -26% | -$199.4K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +3,258 | 3,176 | New | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | -3,258 | 1,385 | -70% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-06 | F | D | 584 | $201.18 | 4,058 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-06 | M | A | 1,873 | $0.00 | 4,642 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-06 | F | D | 407 | $201.18 | 2,769 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-06 | M | A | 1,385 | $0.00 | 3,176 | D | — | — | |
| 5 | Derivative | Restricted Stock Unit | 2026-02-06 | M | D | 1,873 | $0.00 | 3,747 | D | $0.00 · — to 2028-02-06 | 1,873 Common Stock | (F2) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. |
| 6 | Derivative | Restricted Stock Unit | 2026-02-06 | M | D | 1,385 | $0.00 | 1,385 | D | $0.00 · — to 2027-02-07 | 1,385 Common Stock | (F1) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. |